Novo Nordisk Cuts 9,000 Jobs Amid Wegovy Competition

Here’s⁤ a summary of the key information from‍ the provided text:

Novo Nordisk is undergoing restructuring: The company is implementing redundancies (job cuts) ‍as part of a shift in strategy.
New ⁣Leadership: These moves are the first major actions taken by new⁤ CEO⁣ Mike Doustdar, who‍ recently replaced Lars Fruergaard Jørgensen. Doustdar is Iranian-born Austrian-American. Jørgensen had ‍previously hinted at ‍potential redundancies.
Need for Agility: ⁣Doustdar emphasizes the⁣ need for Novo Nordisk to become “faster adn more agile.”
Drug Setbacks: The company has⁤ faced disappointing results with its new obesity drug, CagriSema, which didn’t perform and also Eli Lilly’s Mounjaro ‍in clinical trials.
Compounding Issues: ⁢Sales are also being impacted by “compounding” pharmacies in the ‍US offering cheaper, copycat versions of weight-loss medications.
Profit Warning Expected: Analysts at Bank of America anticipate Novo Nordisk will issue another profit ⁣warning in November, doubting they’ll meet⁤ their sales forecast.